NowPatient

1. 3. Prices are published per selected pack, not as a verified monthly subscription. The default product selector adds shipping and import duties: $75 for injectable packs and $20 for Wegovy Tablets. A separate comparison table shows $0 delivery with optional Core+; the public plan FAQ prices Core+ at $9.99/month for US/rest-of-world users and says free Core can access treatments. Confirm the applicable shipping benefit and total before ordering. The public pages name a UK dispensing pharmacy, Infohealth Pharmacy; US office and dollar pricing do not establish an assigned US dispenser or eligibility in every state. Delivery guidance describes worldwide shipping and cold-chain packaging, with regional variation. The returns page applies UK Consumer Contracts Regulations and non-NHS goods; it is not a verified US prescription refund promise. Telehealth consent references Private Treatment Plan Terms without a navigable public link in the captures; selected-plan renewal, cancellation and US fulfillment remain unconfirmed. No consultation, personal health information or checkout was entered. The Saxenda page expressly names branded prefilled pens.

September 2026

1. 4. NowPatient is a UK company (Infohealth Ltd, GPhC-registered pharmacy) doing business in the US from an Austin, TX office; the site serves a 'United States' region but its own Cancellation & Returns page still quotes EU/UK consumer-contract cancellation law (14-day cooling-off, EU regulations) rather than a US-specific policy — this looks like unlocalized content, flagged rather than silently treated as the US policy. The site sells two separate memberships (Core, $0.00/mo, and Core+, $9.99/mo) that mainly affect free shipping and AI/tool access, not medication price; medication is billed per item, e.g. Mounjaro 'Price $251.98' plus 'Shipment & duties $75.00' unless on Core+, where a $0.00 shipment line appears. So the membership is optional and does not gate access to the drug price. 'Wegovy Injection' and 'Wegovy Tablets' are both sold as separate SKUs; the tablet product's own copy calls it 'Wegovy® Tablets (25 mg)' and 'the first GLP-1 receptor agonist weight-loss medicine available as a tablet' — recorded as 'oral semaglutide' per taxonomy, though whether this exact product is FDA-approved in the US is not stated on the page (one of the site's own blog post titles calls an oral Wegovy pill 'Set to Be Approved by End of 2025', which is inconsistent with the product page selling it now — flagged, not resolved). No specific list of served US states was found on any page checked; prescriber model is a video consultation, i.e. synchronous.